32666680|t|CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis.
32666680|a|OBJECTIVE: To evaluate the CSF levels of chitinase proteins during the presymptomatic and early symptomatic phases of amyotrophic lateral sclerosis (ALS). METHODS: CSF samples were obtained from 16 controls, 55 individuals at-risk for ALS (including 18 carrying a mutation in C9ORF72, 33 in SOD1), 12 ALS patients, and 7 phenoconverters (individuals diagnosed with ALS during follow-up). At-risk individuals and phenoconverters were enrolled through the Pre-fALS study, which includes individuals carrying an ALS-associated gene mutation without disease manifestations at initial assessment. Longitudinal CSF collections, where possible, took place every 3-12 months for ALS patients and every 1-2 years for others. CSF levels of chitotriosidase 1 (CHIT1), chitinase-3-like protein 1 (CHI3L1, YKL-40) and chitinase-3-like protein 2 (CHI3L2, YKL-39) were measured by ELISA, along with CHIT1 activity. Longitudinal changes in at-risk individuals and phenoconverters were fitted to linear mixed effects models. RESULTS: Slowly rising levels of CHIT1 were observed over time in the at-risk individuals (slope 0.059 log10 [CHIT1] per year, P < 0.001). Among phenoconverters, CHIT1 levels and activity rose more sharply (0.403 log10 [CHIT1] per year, P = 0.005; 0.260 log10 [CHIT1 activity] per year, P = 0.007). Individual levels of both CHI3L1 and CHI3L2 remained relatively stable over time in all participant groups. INTERPRETATION: The CHIT1 neuroinflammatory response is a feature of the late presymptomatic to early symptomatic phases of ALS. This study does not suggest a long prodrome of upregulated glial activity in ALS pathogenesis, but strengthens the place of CHIT1 as part of a panel of biomarkers to objectively assess the impact of immune-modulatory therapeutic interventions in ALS.
32666680	49	78	amyotrophic lateral sclerosis	Disease	MESH:D000690
32666680	198	227	amyotrophic lateral sclerosis	Disease	MESH:D000690
32666680	229	232	ALS	Disease	MESH:D000690
32666680	315	318	ALS	Disease	MESH:D000690
32666680	356	363	C9ORF72	Gene	203228
32666680	371	375	SOD1	Gene	6647
32666680	381	384	ALS	Disease	MESH:D000690
32666680	385	393	patients	Species	9606
32666680	445	448	ALS	Disease	MESH:D000690
32666680	589	592	ALS	Disease	MESH:D000690
32666680	751	754	ALS	Disease	MESH:D000690
32666680	755	763	patients	Species	9606
32666680	810	827	chitotriosidase 1	Gene	1118
32666680	829	834	CHIT1	Gene	1118
32666680	837	863	chitinase-3-like protein 1	Gene	1116
32666680	865	871	CHI3L1	Gene	1116
32666680	873	879	YKL-40	Gene	1116
32666680	885	911	chitinase-3-like protein 2	Gene	1117
32666680	913	919	CHI3L2	Gene	1117
32666680	921	927	YKL-39	Gene	1117
32666680	964	969	CHIT1	Gene	1118
32666680	1121	1126	CHIT1	Gene	1118
32666680	1198	1203	CHIT1	Gene	1118
32666680	1250	1255	CHIT1	Gene	1118
32666680	1308	1313	CHIT1	Gene	1118
32666680	1349	1354	CHIT1	Gene	1118
32666680	1413	1419	CHI3L1	Gene	1116
32666680	1424	1430	CHI3L2	Gene	1117
32666680	1515	1520	CHIT1	Gene	1118
32666680	1521	1538	neuroinflammatory	Disease	MESH:D000090862
32666680	1619	1622	ALS	Disease	MESH:D000690
32666680	1701	1704	ALS	Disease	MESH:D000690
32666680	1748	1753	CHIT1	Gene	1118
32666680	1870	1873	ALS	Disease	MESH:D000690
32666680	Association	MESH:D000690	6647
32666680	Association	MESH:D000090862	1118
32666680	Association	MESH:D000690	203228
32666680	Association	MESH:D000690	1118
32666680	Association	MESH:D000690	1116
32666680	Association	MESH:D000690	1117

